Remedy positions itself as a premium AA/AAA game developer with distinctive artistic vision and proprietary technology. The company is undergoing a strategic turnaround under new CEO Jean-Charles Gaudechon (starting March 2026), with major pipeline releases including Control 2 and Max Payne remakes planned for 2026+ to drive revenue growth and profitability targets of doubling 2024 revenue by 2027.
Cyborg Score Rationale
Remedy possesses strong intellectual property, critical acclaim, and ambitious growth targets, but faces near-term challenges with recent operating losses (€16.4M in 2024), slow commercial performance, and leadership transition. The 2026 pipeline offers meaningful upside if execution succeeds.
Top Insights
Leadership transition to new CEO Gaudechon (March 2026) reflects prior commercial underperformance and need for strategic reset
Control 2 and Max Payne remakes in full production represent primary near-term catalysts; company targets €101.4M revenue by 2027 (doubling 2024)
Recent €14.9M impairment charge on FBC: Firebreak multiplayer title signals challenges in live-service execution and shifting strategy
Company maintains second studio in Stockholm and 370+ employees, indicating infrastructure for multi-project execution despite current profitability pressures
Named Competitors
Obsidian Entertainment — Story-driven RPG and action game developer
inXile Entertainment — Narrative-focused RPG developer
Bungie — Sci-fi action game developer
Recent Developments
(March 2026) Jean-Charles Gaudechon appointed as new CEO
(February 2026) Company updates 2026 reporting calendar amid turnaround push
(December 2025) Stock price €15.78, down from €17.11 in December 2025
(November 2025) Control 2 and Max Payne remakes confirmed in full production
Open the full interactive Remedy Entertainment Oyj report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.